Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | The potential of uproleselan in patients with AML

Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the promise of uproleselan, an antagonist of E-selectin, in patients with acute myeloid leukemia (AML), highlighting ongoing clinical trials evaluating this trial in different combinations. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript (edited for clarity)

GSK, Hermavant, AvenCell, Cellularity, CTI Pharma, Kura Onc, Rigel: Advisory board
Takeda, Aptevo, Epizyme. Syntrix: DSMB
AbbVie: Steering committee
BerGenBio: Focus group
Jazz: Grand rounds

GSK, Hermavant, AvenCell, Cellularity, CTI Pharma, Kura Onc, Rigel: Advisory board
Takeda, Aptevo, Epizyme. Syntrix: DSMB
AbbVie: Steering committee
BerGenBio: Focus group
Jazz: Grand rounds

Read more...